LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Lakewood-Amedex Biotherapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.58+0.00 (+0.59%)
Close on Oct 19, 2026
- Market cap
- $828.29K
- P/E (TTM)
- –
- Dividend yield
- –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Lakewood-Amedex Biotherapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in Lakewood-Amedex Biotherapeutics's annual report. Trading prices and yields need FINRA TRACE data.